Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Actions of A-131701, a novel, selective antagonist for alpha-1A compared with alpha-1B adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity.
Hancock AA, Brune ME, Witte DG, Marsh KC, Katwala S, Milicic I, Ireland LM, Crowell D, Meyer MD, Kerwin JF Jr. Hancock AA, et al. Among authors: marsh kc. J Pharmacol Exp Ther. 1998 May;285(2):628-42. J Pharmacol Exp Ther. 1998. PMID: 9580607
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA. Esbenshade TA, et al. J Pharmacol Exp Ther. 2005 Apr;313(1):165-75. doi: 10.1124/jpet.104.078303. Epub 2004 Dec 17. J Pharmacol Exp Ther. 2005. PMID: 15608078
Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists.
Witte DG, Brune ME, Katwala SP, Milicic I, Stolarik D, Hui YH, Marsh KC, Kerwin JF Jr, Meyer MD, Hancock AA. Witte DG, et al. Among authors: marsh kc. J Pharmacol Exp Ther. 2002 Feb;300(2):495-504. doi: 10.1124/jpet.300.2.495. J Pharmacol Exp Ther. 2002. PMID: 11805209
Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.
Esbenshade TA, Browman KE, Miller TR, Krueger KM, Komater-Roderwald V, Zhang M, Fox GB, Rueter L, Robb HM, Radek RJ, Drescher KU, Fey TA, Bitner RS, Marsh K, Polakowski JS, Zhao C, Cowart MD, Hancock AA, Sullivan JP, Brioni JD. Esbenshade TA, et al. J Pharmacol Exp Ther. 2012 Oct;343(1):233-45. doi: 10.1124/jpet.112.194126. Epub 2012 Jul 19. J Pharmacol Exp Ther. 2012. PMID: 22815533
Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious and anesthetized beagle dogs.
Fryer RM, Rakestraw PA, Preusser LC, Brune ME, Carroll WA, Buckner SA, Shieh CC, King LL, Marsh KC, Gopalakrishnan M, Cox BF, Reinhart GA. Fryer RM, et al. Among authors: marsh kc. J Cardiovasc Pharmacol. 2005 Aug;46(2):232-40. doi: 10.1097/01.fjc.0000171755.28317.85. J Cardiovasc Pharmacol. 2005. PMID: 16044036
Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.
Cowart M, Gfesser GA, Browman KE, Faghih R, Miller TR, Milicic I, Baranowski JL, Krueger KM, Witte DG, Molesky AL, Komater VA, Buckley MJ, Diaz GJ, Gagne GD, Zhou D, Deng X, Pan L, Roberts EM, Diehl MS, Wetter JM, Marsh KC, Fox GB, Brioni JD, Esbenshade TA, Hancock AA. Cowart M, et al. Among authors: marsh kc. Biochem Pharmacol. 2007 Apr 15;73(8):1243-55. doi: 10.1016/j.bcp.2007.02.010. Epub 2007 Feb 23. Biochem Pharmacol. 2007. PMID: 17371699
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA. Fox GB, et al. J Pharmacol Exp Ther. 2005 Apr;313(1):176-90. doi: 10.1124/jpet.104.078402. Epub 2004 Dec 17. J Pharmacol Exp Ther. 2005. PMID: 15608077
In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties.
Strakhova MI, Cuff CA, Manelli AM, Carr TL, Witte DG, Baranowski JL, Vortherms TA, Miller TR, Rundell L, McPherson MJ, Adair RM, Brito AA, Bettencourt BM, Yao BB, Wetter JM, Marsh KC, Liu H, Cowart MD, Brioni JD, Esbenshade TA. Strakhova MI, et al. Among authors: marsh kc. Br J Pharmacol. 2009 May;157(1):44-54. doi: 10.1111/j.1476-5381.2009.00236.x. Br J Pharmacol. 2009. PMID: 19413570 Free PMC article.
219 results